Brief: Aura Biosciences Reports Topline Data From A Study Of Belzupacap Sarotalocan (Au-011) VS Plaque Radiotherapy Supporting
22/06/2022 21:32
June 22 (Reuters) - Aura Biosciences Inc AURA.O :
* AURA BIOSCIENCES REPORTS TOPLINE DATA FROM A RETROSPECTIVE
STUDY
OF BELZUPACAP SAROTALOCAN (AU-011) VERSUS PLAQUE RADIOTHERAPY
SUPPORTING THE VALUE OF A VISION PRESERVING THERAPY FOR THE
TREATMENT OF PATIENTS WITH EARLY-STAGE CHOROIDAL MELANOMA
* AURA BIOSCIENCES - ACHIEVED STATISTICALLY SIGNIFICANT
VISION
PRESERVATION COMPARED TO PLAQUE RADIOTHERAPY, CURRENT STANDARD
OF CARE
Source text for Eikon: ID:nBw63Shfba
Further company coverage: AURA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aura Biosciences
See all newsBrief: Aura Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Aura Biosciences - May Offer Securities Up To $500 Million Aggregate
Brief: Aura Biosciences Reports Second Quarter 2026 Financial Results And Recent Business Highlights
U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic
Aura Biosciences Q1 net loss widens on higher R&D costs